Oral Drug That Could Stop Cytokine Storms in Cancer Patients Begins London Trial
A London-based clinical trial has begun recruiting patients for POLB 001, an oral drug designed to prevent the cytokine storm that hospitalises a majority of cancer immunotherapy patients — with no approved

Follow